Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Summit joins the global colorectal fight
The pivotal Harmoni-GI3 study has started enrolling patients.
Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
